FDA Policy In Biosimilars, “Breakthrough” And Social Media Under New Management

Office of Medical Policy’s leadership gets reshuffled following retirement of the long-time CDER denizen Rachel Sherman.

The Office of Medical Policy within the FDA Center for Drug Evaluation and Research will be tackling a host of programmatic issues in the new year with a revamped leadership team following the retirement of office director Rachel Sherman.

Denise Hinton will assume the role of acting OMP director, FDA announced. Hinton is currently the director of the Office of Medical Policy Initiatives (OMPI) and will replaced by her deputy, Chardae Araojo

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America